MESCIUS USA, Inc. Launches ComponentOne 2026 v1 Release
ComponentOne 2026 v1 simplifies date selection in WinForms applications with the new DateRangeEdit control. Developers can provide intuitive date-range selection with built-in presets such as This Week, Last Month, and Next Month, along with multi-calendar support and customizable layouts. It's an easy way to improve scheduling, reporting, and productivity-focused desktop applications. Read the announcement to learn more about ComponentOne's new WinForms control.
With the ComponentOne 2026 v1 release, .NET developers can create interactive flowcharts, organizational charts, and process diagrams with the new FlexDiagram control, now available for WPF, WinUI, and .NET
In this latest release, users can build richer dashboards and data visualizations with enhanced gauge controls for WPF and new gauges for WinUI. Developers can now add informative tick marks and labels, subtle animations, custom face styling, and improved pointer visibility to create more polished radial, linear, and bullet graph visualizations. Read the release article to learn more about enhanced gauges in the ComponentOne 2026 v1 release.
"From datagrids to diagrams, the 2026 v1 release is all about productivity and perfection," said Product Manager
About MESCIUS USA, Inc.: MESCIUS USA, Inc. is one of the world's largest providers of developer components. The company employs 400 people and serves hundreds of thousands of customers worldwide. MESCIUS is committed to providing enterprises around the world with state-of-the-art developer tools and components, software services, and solutions. For more information, visit: https://developer.mescius.com.
All product and company names herein may be trademarks of their respective owners.
View original content:https://www.prnewswire.com/news-releases/mescius-usa-inc-launches-componentone-2026-v1-release-302799823.html
SOURCE MESCIUS USA, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trend Micro Announces Up to ¥10 Billion toward Cyber Resilience Initiative to Strengthen Security for Japanese Organizations in the AI Era
- Chief Revenue Officers Entering 2027 with a "Do More with More" AI Agenda
- OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share